• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    1/26/24 4:31:13 PM ET
    $ACON
    $AFIB
    $APM
    $AQB
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Palisade Bio (NASDAQ:PALI) shares increased by 66.0% to $0.87 during Friday's after-market session. The company's market cap stands at $8.0 million.
    • Aptorum Gr (NASDAQ:APM) stock increased by 18.88% to $2.14. The market value of their outstanding shares is at $11.0 million.
    • NovaBay Pharmaceuticals (AMEX:NBY) shares increased by 15.85% to $0.19. The market value of their outstanding shares is at $1.2 million.
    • MyMD Pharmaceuticals (NASDAQ:MYMD) stock moved upwards by 11.42% to $0.17. The market value of their outstanding shares is at $8.8 million.
    • NuCana (NASDAQ:NCNA) shares increased by 8.47% to $0.32. The market value of their outstanding shares is at $16.8 million.
    • Asensus Surgical (AMEX:ASXC) shares increased by 7.03% to $0.29. The market value of their outstanding shares is at $76.5 million.

    Losers

    • Acutus Medical (NASDAQ:AFIB) shares declined by 9.4% to $0.21 during Friday's after-market session. The market value of their outstanding shares is at $6.1 million.
    • Aclarion (NASDAQ:ACON) stock declined by 6.7% to $2.65. The market value of their outstanding shares is at $2.2 million.
    • Inspire Veterinary (NASDAQ:IVP) stock fell 6.04% to $0.21. The company's market cap stands at $2.3 million.
    • HeartBeam (NASDAQ:BEAT) stock fell 5.92% to $1.75. The company's market cap stands at $46.0 million.
    • Panbela Therapeutics (NASDAQ:PBLA) stock fell 5.8% to $3.9. The market value of their outstanding shares is at $1.8 million.
    • AquaBounty Techs (NASDAQ:AQB) shares fell 4.86% to $2.35. The market value of their outstanding shares is at $9.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AFIB
    $APM
    $AQB

    CompanyDatePrice TargetRatingAnalyst
    Heartbeam Inc.
    $BEAT
    3/27/2026$5.00Buy
    D. Boral Capital
    Palisade Bio Inc.
    $PALI
    3/26/2026$7.00Buy
    H.C. Wainwright
    Heartbeam Inc.
    $BEAT
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Heartbeam Inc.
    $BEAT
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    Heartbeam Inc.
    $BEAT
    12/8/2025$2.50Buy
    H.C. Wainwright
    More analyst ratings

    $ACON
    $AFIB
    $APM
    $AQB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on HeartBeam with a new price target

    D. Boral Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $5.00

    3/27/26 8:50:13 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Palisade Bio with a new price target

    H.C. Wainwright initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    3/26/26 8:49:56 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HeartBeam downgraded by The Benchmark Company with a new price target

    The Benchmark Company downgraded HeartBeam from Buy to Speculative Buy and set a new price target of $8.00

    3/16/26 8:51:28 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ACON
    $AFIB
    $APM
    $AQB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $AFIB
    $APM
    $AQB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    How Decentralized AI is Unlocking Value in Cardiac Diagnostics

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit

    3/27/26 9:30:00 AM ET
    $BEAT
    $GEHC
    $HTFL
    Medical/Dental Instruments
    Health Care
    Medical Electronics
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update

    Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion SKY tokens Key Highlights: Corporate name change from NovaBay Pharmaceuticals, Inc. to Stablecoin Development Corporation; ticker symbol change from NBY to SDEV on the NYSE American, expected to be effective on Friday, April 3, 2026Approximately 2.06 billion SKY tokens held as of March 16, 2026, representing approximately 8.78% of the total supply of SKYApproximately 26.6 million SKY tokens earned in cumulative staking rewards since commencing on-chain staking activitiesApproximately 1.09 billion

    3/23/26 8:30:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

    NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, March 19, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") today announced financial results for the fourth quarter and year ended December 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We are excited to enter 2026 with significant momentum as we continue to advance the development of our P

    3/19/26 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AFIB
    $APM
    $AQB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ACON
    $AFIB
    $APM
    $AQB
    SEC Filings

    View All

    SEC Form 3 filed by new insider Harrison David James

    3 - NuCana plc (0001709626) (Issuer)

    3/24/26 4:20:53 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ortigas-Wedekind Marga

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    3/23/26 5:39:49 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Ferrari Richard

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    3/23/26 5:38:56 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by Aptorum Group Limited

    20-F - Aptorum Group Ltd (0001734005) (Filer)

    3/27/26 4:02:32 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 6-K/A filed by Aptorum Group Limited

    6-K/A - Aptorum Group Ltd (0001734005) (Filer)

    3/26/26 4:30:08 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    3/23/26 8:37:01 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AFIB
    $APM
    $AQB
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ACON
    $AFIB
    $APM
    $AQB
    Financials

    Live finance-specific insights

    View All

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    HeartBeam Reports Fourth Quarter and Full Year 2025 Results

    HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

    3/12/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will

    3/4/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ACON
    $AFIB
    $APM
    $AQB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Palisade Bio Inc.

    SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

    11/14/24 3:35:13 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acutus Medical Inc.

    SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)

    11/14/24 1:03:20 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care